Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT03867799 |
TitleiSCORE: Immunotherapy Sequencing in COlon and REctal Cancer | 阶段
第二阶段
|
Date Added 2019-03-08 |
地点
英国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Nivolumab |
标签
MSS/ MMRp
|
| NCT ID NCT03865082 |
TitleStudy of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) | 阶段
第二阶段
|
Date Added 2019-03-06 |
地点
Arizona, United States
California, United States Texas, United States |
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Ipilimumab, Nivolumab, Tilsotolimod, Opdivo, Yervoy |
标签
MSS/ MMRp
|
| NCT ID NCT03860272 |
TitleFc-Engineered Anti-CTLA-4 Monoclonal Antibody Botensilimab in Advanced Cancer | 阶段
第 1 阶段
|
Date Added 2019-03-01 |
地点
Arizona, United States
California, United States Colorado, United States Connecticut, United States Florida, United States Massachusetts, United States New York, United States Oregon, United States Texas, United States 英国 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Balstilimab, Botensilimab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03851614 |
TitleBasket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors | 阶段
第二阶段
|
Date Added 2019-02-22 |
地点
加拿大
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Cediranib, durvalumab, Olaparib |
标签
MSS/ MMRp
|
| NCT ID NCT03844750 |
TitlePembrolizumab After Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and Who Are Undergoing Liver Surgery | 阶段
第二阶段
|
Date Added 2019-02-18 |
地点
California, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Pembrolizumab, Vactosertib, Keytruda |
标签
MSS/ MMRp
|
| NCT ID NCT03835949 |
TitleStudy of TJ004309 in Combination With Atezolizumab (Tecentriq(R)) in Patients With Advanced or Metastatic Cancer | 阶段
第 1 阶段
|
Date Added 2019-02-11 |
地点
Alabama, United States
Arizona, United States California, United States Texas, United States |
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Atezolizumab, TJ004309 |
标签
MSS/ MMRp
|
| NCT ID NCT03832855 |
Title评估 pING-hHER3FL 的免疫原性 | 阶段
第 1 阶段
|
Date Added 2019-02-06 |
地点
North Carolina, United States
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物
pING-hHER3FL |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03829462 |
Title评估转移性结直肠癌患者服用瑞戈非尼-伊立替康复方制剂与单用瑞戈非尼的效果 | 阶段
第三阶段
|
Date Added 2019-02-04 |
地点
法国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Irinotecan, Regorafenib |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID LUMINESCENCE |
TitleIpilimumab, Maraviroc and Nivolumab (LUMINESCENCE) | 阶段
第 1 阶段
|
Date Added 2019-01-25 |
地点 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Ipilimumab, maraviroc, Nivolumab, Celsentri, Opdivo, Selzentry, Yervoy |
标签
MSS/ MMRp
|
| NCT ID NCT03796884 |
TitleLinaclotide in Treating Patients With Stages 0-3 Colorectal Cancer | 阶段
第二阶段
|
Date Added 2019-01-08 |
地点
Pennsylvania, United States
Washington, United States |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Linaclotide |
标签
MSS/ MMRp
|
